CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
CSL 和 Arcturus Therapeutics 宣佈 Nature Communications 已發佈關鍵數據，證明了 COVID-19 疫苗的功效和耐受性
- Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.
- These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.
- 數據是在日本批准世界上第一款成人自擴增（sa-mRNA）COVID-19 疫苗之後發佈的。
- 這些結果補充了最近公佈的 ARCT-154 數據，這些數據表明，與傳統 mRNA COVID-19 疫苗增強劑相比，免疫原性優於 Omicron BA 4/5，以及後續數據，與傳統 COVID-19 mRNA 疫苗增強劑相比，免疫持續時間更長。
KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL ((ASX:CSL, OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
賓夕法尼亞州普魯士國王和聖地亞哥，2024年5月20日 /PRNewswire/ — 全球生物技術領導者CSL（澳大利亞證券交易所股票代碼：CSL，場外交易代碼：CSLLY）和Arcturus Therapeutics（納斯達克股票代碼：ARCT）今天宣佈 自然通訊 已經公佈了一項評估ARCT、154、一種新型自擴增（sa-mRNA）COVID-19 疫苗和世界上第一個獲批的sa-mRNA COVID-19 疫苗的安全性、免疫原性和有效性的1/2/3a/3b期綜合研究的結果。